Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (771)	12/5/1999 10:26:00 AM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 4474

Some more Ariad questions: Osteoporosis program, GVHD One of the side effects of the HMR - Ariad deal is, if I read the documents correctly, the termination of the Osteoporosis collaboration. That program still had a year to run and HMR was paying for Ariad's research expenses. The agreement was for $30MM for 5yrs. This suggests that Ariad will incur $6MM in increased expenses over the next year to fund this program. Ariad announced that a second (unspecified) milestone had been reached. However, nothing has been said further and it is still preclinical as there has been no presentation of a clinical development program. Anyone know anything more about this? Could ARIA sign up a new partner here? HMR retained some royalty rights and that could make partnering messy! Is my interpretation of the end of the collaboration correct? A second issue is the status of the GVHD program. In their press release on the Phase I GVHD results: corporate-ir.net Ariad stated that Phase II trials may begin by the end of the year. Well, we're at the end of the year folks. Has anyone heard an update? Will the PII be initiated anytime soon? Is this program partnerable? Best regards John de C